Forte Biosciences Inc
FBRX11.435USD
+1.135+11.02%
收盤 11/06, 16:00（美東）報價延遲15分鐘
140.44M總市值
虧損本益比TTM
關於 Forte Biosciences Inc 公司
Forte Biosciences, Inc. 是一家專注於自身免疫和自身免疫相關疾病的臨牀階段生物製藥公司。該公司正在推進其候選產品 FB-102，這是一種專有分子，具有廣泛的自身免疫應用潛力，包括移植物抗宿主病 (GvHD)、白癜風和斑禿 (AA) 等適應症。該公司的 FB-102 項目專注於利用 CD122 拮抗劑解決與這些適應症有關的關鍵途徑。CD122 是 IL-2/IL-15 受體的亞基，IL-2/IL-15 受體是 NK 細胞和 T 細胞亞羣的關鍵調節劑。該公司擁有一項美國專利，用於施用革蘭氏陽性菌和革蘭氏陰性菌以及代謝物的組合，以治療多種皮膚病。該公司的子公司包括 Forte Subsidiary, Inc.、Forte Biosciences Emerald Limited 和 Forte Biosciences Australia Pty Ltd。
Forte Biosciences Inc簡介
公司代碼FBRX
公司名稱Forte Biosciences Inc
上市日期Apr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
員工數量14
證券類型Ordinary Share
年結日Apr 13
公司地址3060 Pegasus Park Drive
城市DALLAS
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編75247
電話13106186994
網址https://www.fortebiorx.com/home/default.aspx
公司代碼FBRX
上市日期Apr 13, 2017
CEODr. Paul A. Wagner, Ph.D.
Forte Biosciences Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 11月4日 週二
更新時間: 11月4日 週二
持股股東
股東類型
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
13.15%
Fred Alger Management, LLC
13.02%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
其他
46.65%
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
13.15%
Fred Alger Management, LLC
13.02%
Janus Henderson Investors
11.22%
OrbiMed Advisors, LLC
9.63%
Tybourne Capital Management (HK) Limited
6.33%
其他
46.65%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
45.54%
Hedge Fund
25.35%
Private Equity
10.18%
Investment Advisor
7.24%
Corporation
3.95%
Individual Investor
1.03%
Research Firm
0.08%
其他
6.64%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
77
10.98M
88.35%
+3.99M
2025Q2
80
7.19M
109.15%
+1.76M
2025Q1
80
5.91M
89.79%
+471.51K
2024Q4
82
5.78M
90.44%
+3.18M
2024Q3
72
948.15K
58.94%
-63.60K
2024Q2
79
972.89K
60.86%
-40.06K
2024Q1
108
982.74K
67.53%
-37.22K
2023Q4
121
973.92K
67.03%
-54.29K
2023Q3
139
1.01M
71.78%
+97.73K
2023Q2
175
455.32K
54.14%
-352.22K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Federated Hermes Global Investment Management Corp.
1.48M
11.89%
+406.41K
+37.90%
Aug 31, 2025
Fred Alger Management, LLC
1.62M
13.02%
+708.04K
+77.75%
Jun 30, 2025
Janus Henderson Investors
1.39M
11.22%
+474.85K
+51.61%
Jun 30, 2025
OrbiMed Advisors, LLC
1.20M
9.63%
+603.87K
+101.82%
Jun 30, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.33%
+166.67K
+26.88%
Jun 30, 2025
BVF Partners L.P.
588.34K
4.73%
-5.94K
-1.00%
Jun 30, 2025
Cable Car Capital LLC
500.00K
4.02%
+280.40K
+127.68%
Jun 30, 2025
Sphera Funds Management Ltd.
495.11K
3.98%
+495.11K
--
Jun 30, 2025
The Vanguard Group, Inc.
486.92K
3.92%
+397.97K
+447.40%
Jun 30, 2025
Ikarian Capital LLC
476.44K
3.83%
-132.78K
-21.80%
Jun 30, 2025
查看更多
持股ETF
更新時間: 20 小時前
更新時間: 20 小時前
機構名稱
佔比
Alger 35 ETF
3.45%
Texas Capital Texas Small Cap Equity Index ETF
0.07%
iShares Micro-Cap ETF
0.02%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
佔比3.45%
Texas Capital Texas Small Cap Equity Index ETF
佔比0.07%
iShares Micro-Cap ETF
佔比0.02%
Dimensional US Core Equity 1 ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Fidelity Nasdaq Composite Index ETF
佔比0%
Alger Mid Cap 40 ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
公告日期
類型
比率
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
